CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Collaboration revenue	$ 76,764	$ 1,413	$ 44,351
Royalty income	3,046	1,826	2,372
Research grants	4,810	4,573	1,968
Other revenues	176	140	256
Total revenues	84,796	7,952	48,947
Expenses:
Research and development	53,183	50,640	49,798
License fees - research and development	578	1,270	1,058
General and administrative	18,248	22,832	25,106
Royalty expense	405	241	237
Depreciation and amortization	2,066	2,853	5,078
Total expenses	74,480	77,836	81,277
Operating income (loss)	10,316	(69,884)	(32,330)
Other income:
Interest income	65	64	1,481
Gain on sale of marketable securities	0	0	237
Total other income	65	64	1,718
Net income (loss) before income taxes	10,381	(69,820)	(30,612)
Income tax benefit	0	95	0
Net income (loss)	$ 10,381	$ (69,725)	$ (30,612)
Net income (loss) per share - basic	$ 0.31	$ (2.14)	$ (0.98)
Weighted-average shares - basic	33,375	32,590	31,219
Net income (loss) per share - diluted	$ 0.31	$ (2.14)	$ (0.98)
Weighted-average shares - diluted	33,494	32,590	31,219